CD19-targeted CAR T cells in refractory antisynthetase syndrome

被引：113

作者：

Mueller, Fabian ^{[1
,2
]}

Boeltz, Sebastian ^{[2
,3
]}

Knitza, Johannes ^{[2
,3
]}

Aigner, Michael ^{[1
,2
]}

Voelkl, Simon ^{[1
,2
]}

Kharboutli, Soraya ^{[1
,2
]}

Reimann, Hannah ^{[1
,2
]}

Taubmann, Jule ^{[2
,3
]}

Kretschmann, Sascha ^{[1
,2
]}

Roesler, Wolf ^{[1
,2
]}

Manger, Bernhard ^{[2
,3
]}

Wacker, Jochen ^{[2
,3
]}

Mougiakakos, Dimitrios ^{[7
]}

Jabari, Samir ^{[4
]}

Schroeder, Rolf ^{[4
]}

Uder, Michael ^{[5
,6
]}

Roemer, Frank ^{[5
,6
]}

Kroenke, Gerhard ^{[2
,3
]}

Mackensen, Andreas ^{[1
,2
]}

Schett, Georg ^{[2
,3
]}

机构：

[1] Friedrich Alexander Univ Erlangen Nurnberg, Dept Internal Med 5 Hematol & Oncol, D-91054 Erlangen, Germany

[2] Friedrich Alexander Univ Erlangen Nurnberg, Deutsch Zentrum Immuntherapie, D-91054 Erlangen, Germany

[3] Friedrich Alexander Univ Erlangen Nurnberg, Dept Internal Med 3 Rheumatol & Immunol, D-91054 Erlangen, Germany

[4] Friedrich Alexander Univ Erlangen Nurnberg, Inst Neuropathol, D-91054 Erlangen, Germany

[5] Friedrich Alexander Univ Erlangen Nurnberg, Inst Radiol, D-91054 Erlangen, Germany

[6] Univ Klinikum Erlangen, D-91054 Erlangen, Germany

[7] Otto von Guericke Univ, Dept Hematol & Oncol, Magdeburg, Germany

来源：

LANCET | 2023年 / 401卷 / 10379期

基金：

英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;

关键词：

D O I：

10.1016/S0140-6736(23)00023-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：815 / 818

页数：4

共 50 条

[21] CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD
Imura, Yuki
Ando, Makoto
Kondo, Taisuke
Ito, Minako
Yoshimura, Akihiko
JCI INSIGHT, 2020, 5 (14)
[22] Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
Bock, Tamara J.
Colonne, Chanukya K.
Fiorenza, Salvatore
Turtle, Cameron J.
NATURE REVIEWS CLINICAL ONCOLOGY, 2025, : 241 - 261
[23] CD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell Malignancies
Miller, Brian C.
Maus, Marcela V.
ONCOLOGY RESEARCH AND TREATMENT, 2015, 38 (12) : 683 - 690
[24] Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells
Zhang, Yuanyuan
Ge, Tong
Huang, Meijuan
Qin, Yun
Liu, Tianjiao
Mu, Wei
Wang, Gaoxiang
Jiang, Lijun
Li, Tongjuan
Zhao, Lei
Wang, Jue
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2023, 18 : 49 - 63
[25] Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL
Park, Jae Hong
Riviere, Isabelle
Wang, Xiuyan
Bernal, Yvette
Purdon, Terence
Halton, Elizabeth
Curran, Kevin Joseph
Sauter, Craig Steven
Sadelain, Michel
Brentjens, Renier J.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[26] Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL
Kang, Liqing
Ma, Jinfeng
Lou, Xiaoyan
Tang, Xiaowen
Xue, Shengli
Chen, Suning
Qiu, Huiying
Miao, Miao
Han, Yue
Wang, Ying
Sun, Aining
Dai, Haiping
Xu, Yang
Li, Limin
Fan, Shengjin
Qian, Chongsheng
Gong, Wenjie
Xu, Mingzhu
Zhou, Haixia
Yao, Zhen
BLOOD, 2023, 142
[27] EFFICACY AND SAFETY OF CD19-TARGETED 19-28Z CAR MODIFIED T CELLS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-ALL
Park, J.
Riviere, I.
Wang, X.
Bernal, Y.
Purdon, T.
Halton, E.
Curran, K.
Sauter, C.
Sadelain, M.
Brentjens, R.
HAEMATOLOGICA, 2015, 100 : 6 - 6
[28] Are we ready for CD19-targeted CAR T-cell therapies in MS?
Giovannoni, Gavin
Hawkes, Christopher H.
Lechner-Scott, Jeannette
Levy, Michael
Yeh, E. Ann
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 70
[29] Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells
Maher, John
CURRENT GENE THERAPY, 2014, 14 (01) : 35 - 43
[30] Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
Gauthier, Jordan
Hirayama, Alexandre V.
Purushe, Janaki
Hay, Kevin A.
Lymp, James
Li, Daniel H.
Yeung, Cecilia C. S.
Sheih, Alyssa
Pender, Barbara S.
Hawkins, Reed M.
Vakil, Aesha
Tinh-Doan Phi
Steinmetz, Rachel N.
Shadman, Mazyar
Riddell, Stanley R.
Maloney, David G.
Turtle, Cameron J.
BLOOD, 2020, 135 (19) : 1650 - 1660

← 1 2 3 4 5 →